XML 32 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2024
Jan. 02, 2024
USD ($)
shares
$ / shares
Award Timing Disclosures [Line Items]    
Award Timing MNPI Disclosure
Timing of Equity Awards
We generally grant equity awards to our employees in line with the following process. As part of the Company’s annual performance and compensation review process, at its regularly scheduled meeting in December, the Compensation and Leadership Development Committee approves preliminary target dollar values for grants of annual stock option, RSU and PRSU awards to our entire equity-eligible employee base, including our NEOs. At that same meeting, it sets a grant date for the annual awards (typically during the first week of January) and a valuation date (typically during the last week in December). Between the valuation date and the grant date, the Compensation and Leadership Development Committee approves final dollar values for each individual receiving a grant. In 2024, the annual grant date was January 2, 2024 and the number of shares subject to each approved option, RSU or PRSU award was determined by dividing the applicable dollar value by the closing price of our stock on the valuation date, December 28, 2023 (and for options, the Black-Scholes value on the same date). Outside of the annual equity award cycle, we may grant awards to employees in connection with a new hire, a promotion, or for other reasons. These grants generally occur on the fifteenth day of the relevant month. In addition, in 2023, we adopted an employee stock purchase plan; however, we have not yet commenced any offering periods under the plan. The Compensation and Leadership Development Committee does not grant equity awards in anticipation of the release of material nonpublic information and we do not time the release of material nonpublic information based on equity award grant dates.
Option exercise price. The exercise price of a newly granted option is the closing price of the Company’s common stock on the Nasdaq stock market on the date of grant.
As required by Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information about the stock options granted to our NEOs on January 2, 2024, within the period beginning four business days before we filed a Form 8-K reporting our preliminary 2023 revenue and 2024 strategic outlook, in advance of our presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name and Principal Position
 
 
Grant
Date
 
 
Number of
Securities
Underlying
the Award
(#)
 
 
Exercise
Price of the
Award
($/Sh)
 
 
Grant Date
Fair Value
of the
Award
($)
 
 
Percentage Change in
the Closing Market Price of
the Securities Underlying the
Award Between the Trading Day
Ending Immediately Prior to the
Disclosure of Material Nonpublic
Information and the Trading Day
Beginning Immediately Following
Disclosure of Material
Nonpublic Information
 
 
Bradley L. Campbell
President and Chief Executive Officer
 
 
1/2/2024
 
 
265,517
 
 
14.24
 
 
2,105,627
 
 
1.0%
 
 
Simon Harford
Chief Financial Officer
 
 
1/2/2024
 
 
99,073
 
 
14.24
 
 
785,678
 
 
1.0%
 
 
Ellen S. Rosenberg
Chief Legal Officer and Corporate Secretary
 
 
1/2/2024
 
 
108,980
 
 
14.24
 
 
864,243
 
 
1.0%
 
 
David M. Clark
Chief People Officer
 
 
1/2/2024
 
 
83,221
 
 
14.24
 
 
659,967
 
 
1.0%
 
 
Jeffrey P. Castelli
Chief Development Officer
 
 
1/2/2024
 
 
99,073
 
 
14.24
 
 
785,678
 
 
1.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Award Timing Method We generally grant equity awards to our employees in line with the following process. As part of the Company’s annual performance and compensation review process, at its regularly scheduled meeting in December, the Compensation and Leadership Development Committee approves preliminary target dollar values for grants of annual stock option, RSU and PRSU awards to our entire equity-eligible employee base, including our NEOs. At that same meeting, it sets a grant date for the annual awards (typically during the first week of January) and a valuation date (typically during the last week in December). Between the valuation date and the grant date, the Compensation and Leadership Development Committee approves final dollar values for each individual receiving a grant. In 2024, the annual grant date was January 2, 2024 and the number of shares subject to each approved option, RSU or PRSU award was determined by dividing the applicable dollar value by the closing price of our stock on the valuation date, December 28, 2023 (and for options, the Black-Scholes value on the same date). Outside of the annual equity award cycle, we may grant awards to employees in connection with a new hire, a promotion, or for other reasons. These grants generally occur on the fifteenth day of the relevant month. In addition, in 2023, we adopted an employee stock purchase plan; however, we have not yet commenced any offering periods under the plan.  
Award Timing Predetermined true  
Award Timing MNPI Considered true  
Award Timing, How MNPI Considered The Compensation and Leadership Development Committee does not grant equity awards in anticipation of the release of material nonpublic information and we do not time the release of material nonpublic information based on equity award grant dates.  
MNPI Disclosure Timed for Compensation Value false  
Awards Close in Time to MNPI Disclosures, Table
Option exercise price. The exercise price of a newly granted option is the closing price of the Company’s common stock on the Nasdaq stock market on the date of grant.
As required by Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information about the stock options granted to our NEOs on January 2, 2024, within the period beginning four business days before we filed a Form 8-K reporting our preliminary 2023 revenue and 2024 strategic outlook, in advance of our presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name and Principal Position
 
 
Grant
Date
 
 
Number of
Securities
Underlying
the Award
(#)
 
 
Exercise
Price of the
Award
($/Sh)
 
 
Grant Date
Fair Value
of the
Award
($)
 
 
Percentage Change in
the Closing Market Price of
the Securities Underlying the
Award Between the Trading Day
Ending Immediately Prior to the
Disclosure of Material Nonpublic
Information and the Trading Day
Beginning Immediately Following
Disclosure of Material
Nonpublic Information
 
 
Bradley L. Campbell
President and Chief Executive Officer
 
 
1/2/2024
 
 
265,517
 
 
14.24
 
 
2,105,627
 
 
1.0%
 
 
Simon Harford
Chief Financial Officer
 
 
1/2/2024
 
 
99,073
 
 
14.24
 
 
785,678
 
 
1.0%
 
 
Ellen S. Rosenberg
Chief Legal Officer and Corporate Secretary
 
 
1/2/2024
 
 
108,980
 
 
14.24
 
 
864,243
 
 
1.0%
 
 
David M. Clark
Chief People Officer
 
 
1/2/2024
 
 
83,221
 
 
14.24
 
 
659,967
 
 
1.0%
 
 
Jeffrey P. Castelli
Chief Development Officer
 
 
1/2/2024
 
 
99,073
 
 
14.24
 
 
785,678
 
 
1.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Bradley L. Campbell [Member]    
Awards Close in Time to MNPI Disclosures    
Name   Bradley L. Campbell
Underlying Securities | shares   265,517
Exercise Price | $ / shares   $ 14.24
Fair Value as of Grant Date | $   $ 2,105,627
Underlying Security Market Price Change   0.01
Simon Harford [Member]    
Awards Close in Time to MNPI Disclosures    
Name   Simon Harford
Underlying Securities | shares   99,073
Exercise Price | $ / shares   $ 14.24
Fair Value as of Grant Date | $   $ 785,678
Underlying Security Market Price Change   0.01
Ellen S. Rosenberg [Member]    
Awards Close in Time to MNPI Disclosures    
Name   Ellen S. Rosenberg
Underlying Securities | shares   108,980
Exercise Price | $ / shares   $ 14.24
Fair Value as of Grant Date | $   $ 864,243
Underlying Security Market Price Change   0.01
David M. Clark [Member]    
Awards Close in Time to MNPI Disclosures    
Name   David M. Clark
Underlying Securities | shares   83,221
Exercise Price | $ / shares   $ 14.24
Fair Value as of Grant Date | $   $ 659,967
Underlying Security Market Price Change   0.01
Jeffrey P. Castelli [Member]    
Awards Close in Time to MNPI Disclosures    
Name   Jeffrey P. Castelli
Underlying Securities | shares   99,073
Exercise Price | $ / shares   $ 14.24
Fair Value as of Grant Date | $   $ 785,678
Underlying Security Market Price Change   0.01